Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010019097) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/019097 International Application No.: PCT/SE2009/050924
Publication Date: 18.02.2010 International Filing Date: 11.08.2009
IPC:
A61K 31/439 (2006.01) ,A61P 11/06 (2006.01) ,A61P 11/08 (2006.01) ,C07D 471/08 (2006.01) ,A61K 31/438 (2006.01) ,A61K 31/4468 (2006.01) ,C07D 261/08 (2006.01) ,C07D 271/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
439
the ring forming part of a bridged ring system, e.g. quinuclidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
06
Antiasthmatics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11
Drugs for disorders of the respiratory system
08
Bronchodilators
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
08
Bridged systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
438
the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4468
having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
261
Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
02
not condensed with other rings
06
having two or more double bonds between ring members or between ring members and non-ring members
08
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
271
Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
02
not condensed with other rings
06
1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Applicants:
AVITABILE, Barbara Guiseppina [IT/GB]; GB (UsOnly)
NADIN, Alan John [GB/GB]; GB (UsOnly)
RAY, Nicholas Charles [GB/GB]; GB (UsOnly)
ASTRAZENECA AB [SE/SE]; S-SE-151 85 Södertälje, SE (AllExceptUS)
PULMAGEN THERAPEUTICS (SYNERGY) LIMITED [GB/GB]; Fulmer Hall Windmill Road Fulmer Slough Berkshire SL3 6HD, GB (AllExceptUS)
Inventors:
AVITABILE, Barbara Guiseppina; GB
NADIN, Alan John; GB
RAY, Nicholas Charles; GB
Agent:
ASTRAZENECA AB; AstraZeneca Intellectual Property S-151 85 Södertälje, SE
Priority Data:
0814729.012.08.2008GB
Title (EN) PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT
(FR) PRODUIT PHARMACEUTIQUE CONSTITUÉ D'UN ANTAGONISTE DU RÉCEPTEUR MUSCARINIQUE ET D'UN SECOND PRINCIPE ACTIF
Abstract:
(EN) The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is selected from a phosphodiesterase inhibitor, a modulator of chemokine receptor function, an inhibitor of kinase function, a protease inhibitor, a steroidal glucocorticoid receptor agonist, a non-steroidal glucocorticoid receptor agonist and a purinoceptor antagonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
(FR) L'invention concerne un produit pharmaceutique, un kit ou une composition renfermant un premier principe actif qui est un antagoniste choisi du récepteur muscarinique et un second principe actif qui est choisi parmi un inhibiteur de phosphodiestérase, un modulateur de la fonction d'un récepteur de cytokine, un inhibiteur de la fonction d'une kinase, un inhibiteur de protéase, un agoniste des récepteurs des glucocorticoïdes stéroïdiens, un agoniste des récepteurs des glucocorticoïdes non stéroïdiens et un antagoniste de purinocepteur, utile dans le traitement de maladies respiratoires telles que la broncho-pneumopathie chronique obstructive et l'asthme.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)